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Abstract
Introduction Sites of chronic inflammation are often associated
with the establishment and growth of various malignancies
including breast cancer. A common inflammatory condition in
humans is autoimmune arthritis (AA) that causes inflammation
and deformity of the joints. Other systemic effects associated
with arthritis include increased cellular infiltration and
inflammation of the lungs. Several studies have reported
statistically significant risk ratios between AA and breast cancer.
Despite this knowledge, available for a decade, it has never
been questioned if the site of chronic inflammation linked to AA
creates a milieu that attracts tumor cells to home and grow in the
inflamed bones and lungs which are frequent sites of breast
cancer metastasis.
Methods To determine if chronic inflammation induced by
autoimmune arthritis contributes to increased breast cancer-
associated metastasis, we generated mammary gland tumors in
SKG mice that were genetically prone to develop AA. Two
breast cancer cell lines, one highly metastatic (4T1) and the
other non-metastatic (TUBO) were used to generate the tumors
in the mammary fat pad. Lung and bone metastasis and the
associated inflammatory milieu were evaluated in the arthritic
versus the non-arthritic mice.
Results We report a three-fold increase in lung metastasis and
a significant increase in the incidence of bone metastasis in the
pro-arthritic and arthritic mice compared to non-arthritic control
mice. We also report that the metastatic breast cancer cells
augment the severity of arthritis resulting in a vicious cycle that
increases both bone destruction and metastasis. Enhanced
neutrophilic and granulocytic infiltration in lungs and bone of the
pro-arthritic and arthritic mice and subsequent increase in
circulating levels of proinflammatory cytokines, such as
macrophage colony stimulating factor (M-CSF), interleukin-17
(IL-17), interleukin-6 (IL-6), vascular endothelial growth factor
(VEGF), and tumor necrosis factor-alpha (TNF-alpha) may
contribute to the increased metastasis. Treatment with anti-IL17
+ celecoxib, an anti-inflammatory drug completely abrogated the
development of metastasis and significantly reduced the primary
tumor burden.
Conclusions The data clearly has important clinical implications
for patients diagnosed with metastatic breast cancer, especially
with regards to the prognosis and treatment options.
Introduction
Metastasis is regulated not only by intrinsic genetic changes
in malignant cells, but also by the microenvironment. Several
studies have demonstrated that sites of chronic inflammation
are often associated with the establishment and growth of var-
ious malignancies [1]. A common inflammatory condition in
humans is autoimmune arthritis (AA) that causes inflammation
and deformity of the joints. Other systemic effects associated
with AA include increased cellular infiltration and inflammation
of the lungs and blood vessels (vasculitis), and weakening ofPage 1 of 15
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ent diseases, some of the underlying processes that contrib-
ute to the disorders of the joints and connective tissue that
characterize AA also affect cancer progression and metasta-
sis. In addition, the immune system appears to play an over-
seer's role in both diseases as reviewed by Ziegler [2]. The
most striking link between the two diseases came from a long-
term community-based prospective study of the influence of
inflammatory polyarthritis (IP) in cancer incidence and survival
[3]. The authors reported that inflammatory arthritis increases
the risk of dying from cancer (at least double the risk of the
general population). Several studies have also reported statis-
tically significant risk ratios between AA and various malignan-
cies including breast, lung, hematopoietic, non-melanotic skin,
kidney, and colon [4-6].
Despite this knowledge, which has been available for a dec-
ade, there has been minimal research linking arthritis with met-
astatic breast cancer. It has never been questioned if a site of
chronic inflammation linked to AA creates a milieu that attracts
tumor cells to home and grow in the inflamed site. The lungs
and bones are frequent sites of breast cancer metastasis [7].
The preference of breast cancer cells to grow in the bone and
lung is underscored by the fact that 65 to 75% of patients with
advanced disease develop bone or lung metastasis [8]. Yet, it
is not known why and how breast cancer cells prefer to colo-
nize these organs. There are no methods to predict the risk of
breast cancer-associated metastasis and current treatments
have notable limitations. We hypothesize that chronic inflam-
matory milieu and osteoclastic bone resorption caused by AA
and the lung inflammation associated with it may influence the
recruitment, retention, and proliferation of tumor cells in the
bone and lungs.
In this study, we determined if chronic inflammation in the
bones and lungs induced by AA contribute to increased breast
cancer-associated bone and lung metastasis. We have used a
recently established animal model of spontaneous autoim-
mune arthritis known as SKG mice. These mice are on the
Balb/c background and carry a mutation of the gene encoding
a SH2 domain of ZAP-70, a key signal transduction molecule
in T cells, and spontaneously develop T cell-mediated chronic
AA [9]. The mutation impairs positive and negative selection of
T cells in the thymus, leading to thymic production of arthri-
togenic autoimmune CD4+ T cells. The mice succumb to sym-
metrical joint swelling beginning in the small joints of the digits
and progressing to larger joints, accompanied by severe syn-
ovitis with formation of pannus invading and eroding adjacent
cartilage and subchondral bone.
Genetic deficiency of IL-6, IL-1, or TNF-α inhibit development
of AA in SKG mice [10], similar to the effects of anticytokine
therapy in human arthritis [11]. These clinical and immun-
opathological characteristics of AA in these mice make the
strain a suitable model for testing our hypothesis. When these
arthritic mice were induced to develop metastatic mammary
gland tumors, a significant increase in lung and bone metasta-
sis were observed compared with the non-arthritic mice. Fur-
thermore, the severity of arthritis was amplified by factors
associated with the metastatic compared with the non-meta-
static tumor cells. We have identified some of the key pro-
inflammatory factors that may partially contribute to the
increased incidence of secondary metastasis. Overall, our
data suggests a novel link between AA-induced inflammation
and secondary metastasis associated with breast cancer.
Materials and methods
Mice
SKG mice have been established from a closed breeding col-
ony of Balb/c mice [9]. Two sets of SKG breeding pairs were
purchased from CLEA International (Tokyo, Japan) and were
maintained in our animal facility. All protocols were approved
by the Mayo Clinic Internal Animal Care Review Committee.
Induction of arthritis and tumor inoculation
Two month old mice were given a single intraperitoneal (ip)
injection of 2 mg zymosan A in 100 μl of 0.15 M sodium chlo-
ride (NaCl) per mouse [12] and joint swelling was macroscop-
ically examined starting at 14-days post zymosan A treatment.
Thirty days post zymosan A treatment, more than 95% of the
mice develop polyarthritis in small and large joints. At this time,
mice were injected with 1 × 106 (in 100 μl of PBS) syngeneic
breast cancer cells (4T1: metastatic or TUBO: non-meta-
static) in the mammary fat pad. Age-matched SKG mice with-
out zymosan A were used as the pro-arthritic model, and Balb/
c mice were used as the non-arthritic controls. As per Institu-
tional Animal Care and Use Committee regulations, we sacri-
ficed the mice when tumors in the mammary fat pad reached
10% of the body weight. All mice were injected with the same
number of tumor cells. When tumors in one group of mice
reached more than 10% of their body weight, all mice were
sacrificed and analysis was conducted. In our study the time-
point at which the mice were analyzed for metastasis was four
weeks after tumor inoculation.
Zymosan A was purchased from Sigma-Aldrich, USA (St
Louis, MO, USA). A 1% solution of zymosan was made in 0.15
M NaCl, placed in a boiling water bath for one hour, centri-
fuged for 30 minutes at 4000 rpm and the residue suspended
evenly in the 0.15 M NaCl to the desired concentration. It is
established that the glucose polymer B-1,3-D-glucans (B-glu-
cans), the main constituents of zymosan A, are responsible for
the arthritogenic effect [12].
Scoring of joint swelling
Joint swelling was monitored by inspection and scored as fol-
lows: 0 = no joint swelling; 0.1 = swelling of one finger joint;
0.5 = mild swelling of wrist or ankle; 1.0 = severe swelling of
wrist or ankle. Scores for all fingers of forepaws and hindpaws,Page 2 of 15
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is followed according to previously published protocol [9].
Cell culture
The 4T1 mammary carcinoma cell line was purchased from
The American Type Cell Culture Collection (Manassas, VA,
USA) and the TUBO mammary carcinoma cell line was gener-
ously provided by Dr Joseph Lustgurten, Mayo Clinic College
of Medicine. 4T1 and TUBO cells were maintained in RPMI-
1640 medium supplemented with 10% FBS, 1% Glutamax-1
and 1% penicillin-streptomycin. Cells were maintained at log
phase at 37°C with 5% carbon dioxide. 4T1 is a highly meta-
static breast cancer cell line derived from a spontaneously
arising BALB/c mammary tumor. TUBO is a cloned cell line
established from a mammary carcinoma of the Her2-neu trans-
genic mice also on the Balb/c background. TUBO is consid-
ered to be a nonmetastatic cell line.
Measurement of circulating cytokines
The RayBio® Custom Mouse Cytokines Antibody Array kit was
purchased from RayBiotech (Norcross, GA, USA) and used
according to the manufacturer's instructions. Briefly, after
blocking with 1 × blocking buffer (provided by the manufac-
turer), membranes were incubated for 1.5 hours with the
experimental serum (10-fold diluted with 1 × blocking buffer).
The membranes were washed and incubated with biotin-con-
jugated antibodies for 1.5 hours. The membranes were
washed again and incubated with streptavidin-conjugated
horseradish peroxidase for two hours, washed, and developed
using an enhanced chemiluminescent substrate for horserad-
ish peroxidase. Chemiluminescence was detected using a
EpiChemi3® Darkroom imaging system and LabWorks® den-
sitometry software (both from UVP Bioimaging, Upland, CA,
USA). Data was corrected for background signal and normal-
ized to positive controls using RayBio® Analysis Tool software
(UVP Bioimaging, Upland, CA, USA).
Histology
Lungs were formalin fixed in 10% neutral-buffered formalin
(pH 6.8 to 7.2) for a minimum of 24 hours. Paraffin-embedded
blocks were prepared by the Histology Core at The Mayo
Clinic and 4-micron thick sections were cut for H&E staining
and for immuno-staining. To determine macrophage infiltration
in the lungs, F4/80 (Abcam, Cambridge, MA, USA; CI:A3-1)
antibody was used at 1:50 dilution and incubated overnight at
4°C followed by DAKO goat anti-rat secondary (1:100 dilu-
tion; Dako North America, Carpinteria, CA, USA). For neu-
trophil staining, the standard protocol provided by the
Naphthol AS-D Chloroacetate Esterase, (Sigma, St Louis,
MO, USA; Cat: # 91C-1Kit) was used. We recognize that
CAE also may stain for other myeloid cells such as mast cells
and macrophages; however, neutrophils stain purple and have
the typical morphology as shown in the magnified image. The
kit used to stain neutrophils is most commonly used to detect
neutrophils in tissue sections that have been paraffin embed-
ded (as indicated in the kit fact sheet). Slides examined under
light microscopy and pictures taken at 200× magnification.
For bones, the fore limb and hind limb were dissected from the
mice and immersed in 10% neutral-buffered formalin (pH 6.8
to 7.2) overnight. For decalcification, Cal-Rite (Richard Allan
Scientific, Kalamazoo, MI, USA), a formic acid decalcification
agent was used for about 72 hours followed by the conven-
tional processing method. Masson trichome staining was used
to determine levels of osteoclasts. Cyclo-oxygenase-2 (COX-
2) and pancytokeratin (Santa Cruz Biotechnologies, Santa
Cruz, CA, USA) antibodies were used at 1:50 and incubated
overnight at 4°C followed by the DAKO anti-goat secondary
(Dako North America; 1:100 dilution) for 45 minutes at room
temperature for COX-2. For pancytokeratin staining, DAKO
anti-mouse secondary (Dako North America) was used at
1:100 for 45 minutes at room temperature. 3, 3"–diaminoben-
zidine was used as the chromogen and hematoxylin was used
as counterstain. Slides were examined under light microscopy
and pictures taken at 200× magnification.
Faxitron imaging
The Faxitron is a 160-kVp x-ray machine that was adapted from
an x-ray imaging unit through modifications to facilitate experi-
mental irradiation and imaging. The Faxitron model CP160
(Faxitron X-Ray Corp., Wheeling, IL, USA) is a commercially
available x-ray tube machine that is designed for animal irradi-
ation [13]. The analysis was conducted by a Mayo Clinic radi-
ologist and lately in Carolinas Medical Center within the
Department of Orthopedic Surgery.
Invasion assay with bronchoalveolar lavage fluid
Mice were sacrificed by carbon dioxide inhalation, a tracheal
cannula was inserted, and bronchoalveolar lavage (BAL) fluid
was collected by lavage of the lungs, three times with 1 ml of
cold PBS. BAL cells were pelleted by centrifugation and the
supernatant collected for tumor invasion assays.
Invasion of 4T1 was tested using a standard trans-well
matrigel assay [14]. The inserts (8.0 μM Falcon 353097) were
coated with 5 μl of 7.6 μg/μl growth factor-reduced marigel
(BD Biosciences, San Jose, CA, USA) diluted 1:5 in serum
free RPMI (SF) media. Thirty minutes post incubation at 37°C,
500 μl BAL in SF media was added into a 24-well plate. Com-
plete RPMI media with 10% FCS was used as a positive con-
trol and SF media served as the negative control. In to 300 μl
SF media, 5 × 104 4T1 cells were added on the matrigel
coated insert. Fifteen hours post incubation at 37°C, non-
invaded cells were harvested from the top of the insert. Inserts
were inverted and stained with 30 μl of crystal violet (0.5%
crystal violet/20% methanol) for 5 to 10 minutes, rinsed with
d-H20 and left to dry. The membranes were cut and added to
200 μl 10% acetic acid solution in a 96-well plate, incubated
for 10 minutes, removed and read on a spectrophotometer atPage 3 of 15
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ing of the sample/average reading of the control) × 100.
Study design for the IL-17 treatment
To test the efficacy of anti-IL-17 antibody treatment on breast
cancer-associated metastasis, three month old SKG mice
were injected with 1 × 106 (in 100 μl of PBS) 4T1 cells in the
mammary fat pad. When the tumors were 0.2 g or more, three
ip injections of 5 μg/ml of anti-IL17 antibody (BD Pharmingen,
San Diego, CA, USA; Cat#560268) once a week was admin-
istered. Celecoxib (20 mg/kg in 100 μl 10% DMSO) was gav-
aged starting at the same time as the IL-17 antibody but was
given daily until sacrifice. One week after the last injection,
mice were sacrificed. Untreated SKG mice challenged with
4T1 cells and the SKG challenged with 4T1 cells and injected
with 5 μg/ml rat immunoglobulin (Ig) G1 control antibody (BD
Pharmingen, Cat# 554682) in 100 μl PBS were used as con-
trols. Experimental groups were: 1) SKG + 4T1 (celecoxib
only); 2) SKG + 4T1(IL-17 only); 3) SKG + 4T1(IL-
17+celecoxib); 4) SKG + 4T1 (control antibody + DMSO);
and 5) SKG + 4T1 (no treatment).
Statistical analysis
Student's t-test was used for comparing the level of signifi-
cance between the experimental groups. Correlation coeffi-
cient was determined using the JMP statistical discovery
software (SAS Institute Inc., Cary, NC, USA).
Results
Metastatic breast cancer cells may contribute to the 
severity of arthritis in the SKG mice
In pathogen-free facilities, the SKG mice remain pro-arthritic
with no macroscopic signs of joint swelling until treated with
zymosan A (a yeast cell wall extract) [12]. Within 30 to 45 days
of zymosan treatment, there is clearly macroscopic evidence
of joint swelling in the fingers and in the fore and hind limbs
(Figures 1a to 1f). SKG, SKG + zymosan (30-days post
zymosan), and Balb/c control mice were challenged with 1 ×
106 syngeneic breast cancer cells (4T1 being metastatic and
TUBO being non-metastatic) in the mammary fat pad. Com-
pared with the Balb/c ± zymosan and the pro-arthritic SKG
mice (Figures 1a to 1c), the joint swelling was two-fold higher
in the SKG + zymosan mice ± TUBO tumors (Figures 1d and
1e) and five-fold higher in the SKG + zymosan mice bearing
the 4T1 tumors (Figure 1f). Importantly, the SKG + zymosan
mice bearing the 4T1 tumors had a two-fold increase in joint
swelling compared with the same mice bearing the TUBO
tumors or no tumors (Figure 1f compared with Figure 1d and
1e), suggesting that the metastatic 4T1 breast cancer cells
may have the potential to augment the severity of arthritis. This
is further elucidated in Figure 1g, where the arthritis score in
SKG + zymosan + 4T1 mice was significantly higher than in
the SKG + zymosan + TUBO mice (P < 0.01); while the arthri-
tis score in the SKG + zymosan + TUBO mice remained
exactly the same as SKG + zymosan mice without any tumor
(Figure 1g) suggesting that TUBO cells did not affect the
severity of arthritis in these mice. There were no macroscopic
signs of arthritis detected in the SKG + 4T1 mice (Figure 1g).
Similar results were seen in eight mice per experimental group.
Of note is that none of the Balb/c controls with or without
zymosan or SKG without zymosan showed any signs of inflam-
mation (Figures 1a to 1c and 1g).
Histological examination of the bone sections clearly showed
that compared with the non-tumor-bearing SKG and the
TUBO tumor-bearing SKG mice, the 4T1 tumor-bearing SKG
mice had severe inflammation with a high degree of cellular
infiltration in the joints (Figures 1i, k, and 1m). Similarly, higher
severity of synovial hyperplasia and erosion of articular carti-
lage in the phalangeal joints of the hind limb along with severe
cellular infiltration was found in the 4T1 tumor-bearing SKG +
zymosan mice (Figure 1n) compared with the joints of control
SKG + zymosan mice with no tumors (Figure 1j) or in the
TUBO-bearing SKG + zymosan mice (Figure 1l). It must be
acknowledged that although all SKG + zymosan mice showed
high infiltration, the severity of infiltration was highest in the
SKG + zymosan + 4T1 mice (Figures 1j, l, and 1n). Inflamma-
tion was absent in control Balb/c mice, while in the SKG and
SKG + TUBO mice low-level infiltration was evident (Figures
1h, i, and 1k). High cellular infiltration in the 4T1-bearing SKG
+ zymosan mice was associated with increased bone destruc-
tion as evidenced by the increased osteoclasts in these mice
(Figure 1t) as compared with SKG + zymosan (Figure 1s) or
SKG without tumors (Figure 1r). There were no detectable
osteoclasts in any of the Balb/c mice (Figures 1o to 1q) or
TUBO injected mice (data not shown). SKG + 4T1 mice
showed very similar osteoclast expression as SKG + zymosan
+ 4T1 (data not shown). Taken together these data suggest
that the metastatic 4T1 breast cancer cells may contribute to
the vicious cycle of osteolytic destruction. Several sections
from eight mice per experimental group were examined with
similar results. Sections of the distal hind limb joints are
shown.
Significant increase in lung metastasis in the arthritic 
versus non-arthritic mice
Next, we questioned if the primary tumor burden was affected
by the arthritic milieu in the SKG mice. In SKG mice, both 4T1
and TUBO primary tumor burden was significantly higher com-
pared with the non-arthritic Balb/c mice (Figures 2a and 2b **
P < 0.01, * P < 0.05). However, to our surprise the primary
tumor burden in the SKG + zymosan mice was not significantly
different from the Balb/c control mice (Figures 2a and 2b) sug-
gesting that the primary tumor burden was not further influ-
enced by zymosan-induced arthritis. We do not understand at
this time why the tumor burden in SKG + zymozan and Balb/c
were similar. Nevertheless, secondary metastasis to the lungs
and bone was significantly altered in both the SKG and SKG
+ zymosan mice as discussed below.Page 4 of 15
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Figure 1
Induction of arthritis in SKG micei i i   i . (a to f) Images of the hind and fore limbs (a) control Balb/c mice (no inflammation); (b) Balb/c mice+Zymosan (no 
inflammation); (c) SKG mice (no inflammation); (d) SKG mice + Zymosan A (moderate inflammation); (e) SKG mice +Zymosan A + TUBO (moder-
ate inflammation); (f) SKG mice + Zymosan A + 4T1 cells (severe inflammation). (g) Scoring of joint swelling: Compared with SKG mice + Zymosan 
A or SKG mice +Zymosan A + TUBO, a significant increase in joint swelling was observed in SKG mice injected with Zymosan A and challenged 
with 4T1 cells (P < 0.05). (h to n) H&E staining of sections from the joints: (h) Balb/c mice; (i) SKG mice; (j) SKG mice + Zymosan A without tumor 
challenge (moderate inflammation); (k) SKG mice + TUBO cells; (l) SKG mice + Zymosan A + TUBO cells showing some erosion of articular carti-
lage; (m) SKG mice + 4T1 cells showing severe inflammation in the phalangeal joints; (n) SKG mice + Zymosan A + 4T1 cells showing severe syn-
ovial hyperplasia and erosion of articular cartilage and bone in phalangeal joints with severe inflammation; (o to t) Masson trichome staining of 
sections from the bones: (o) Balb/c mice; (p) Balb/c mice + Zymosan A; (q) Balb/c mice +Zymosan A + 4T1; (r) SKG mice; (s) SKG mice + 
Zymosan A (arrow represents osteoclast); (t) SKG + Zymosan A + 4T1 (multiple osteoclasts marked with arrows). The H&E images of the joints 
were taken at 200 × magnification and the Masson Trichome bone images taken at 400 × magnification.
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metastasis in the 4T1 tumor-bearing SKG and SKG +
zymosan mice compared with the 4T1 tumor-bearing Balb/c
mice (Figures 3a to 1j). All of the SKG (8/8 mice) and SKG +
zymosan (9/9 mice) mice developed lung metastasis with the
4T1 tumors compared with only 27% (3/11 mice) of the Balb/
c mice (Figure 3j). The number and size of the lung lesions
were also found to be significantly higher in the SKG versus
the Balb/c mice (data not shown). This result is especially sig-
nificant because it represents true metastasis arising from the
primary mammary gland tumor. Lungs from TUBO-challenged
mice show no metastatic lesions in the Balb/c or SKG mice,
albeit 2/8 SKG + zymosan mice developed lung lesions with
TUBO cells (Figures 3d to 3f, and 3j). There were no meta-
static lesions in lungs of control Balb/c, SKG, and SKG-
zymosan mice without tumor challenge (Figures 3a to 3c, and
3j). A representative lung from each experimental group is
shown (Figure 3a to 3i). It must be noted that the difference in
metastasis was certainly not due to primary tumor size,
because the zymosan group and Balb/c group had no differ-
ence in primary tumors but had significant difference in metas-
tasis. In addition, the primary tumor weight of TUBO and 4T1
was similar but metastasis was significantly different. In any
case, the smallest tumor was still pretty large, that is, 1 g or
1000 mgs.
To investigate a mechanism of the increased lung metastasis,
we first examined the lung histology from the various mice. It
became apparently clear from the H&E staining that all lungs
that developed metastasis were packed with inflammatory cel-
lular infiltrates characterized by prominent neutrophilic and
granulocytic cells and activated macrophages (Figure 3n to
3w). Along with the cellular infiltrates, epithelial metastatic
lesions were identified in the lungs as indicated by the solid
yellow arrowheads (Figures 3s, u, and 3w). Infiltration in the
SKG + 4T1 and SKG + zymosan + 4T1 lungs (Figures 3u and
3w) was significantly higher than in SKG (Figure 3n), SKG +
zymosan (Figure 3o), and SKG + TUBO (Figure 3q) mice. Infil-
tration in the SKG + 4T1 or SKG + zymosan + 4T1 lungs was
significantly higher than in 4T1 bearing Balb/c mice ±
zymosan mice (compare Figures 3t and 3v with 3u and 3w).
Interestingly, the TUBO and 4T1-bearing Balb/c showed com-
pletely normal lung architecture with no infiltration (Figures 3p
and 3r) and in contrast the SKG + zymosan + TUBO showed
significant infiltration (compare Figure 3r with 3s) but only in
the mice that developed metastasis (Figure 3j). Data suggest
a high degree of correlation (correlation coefficient of 0.99)
between the level of cellular infiltration in the lungs and the
severity of lung metastasis.
The next obvious question was whether the severity of lung
metastasis follows the severity of arthritis. A representative
lung and bone section from a 4T1 tumor-bearing SKG mouse
is shown in Figures 3k and 3l, in which severe inflammation in
the fore and hind limbs correlated with severe metastatic lung
lesions. Significant correlation exists between severity of joint
inflammation (arthritis) and the development of lung metasta-
sis in the 4T1 tumor-bearing SKG and SKG + zymosan mice
(correlation coefficient of 0.93 and 0.90 respectively; Figure
3m).
To further demonstrate the chemotactic microenvironment in
the lungs of arthritic versus non-arthritic mice, specific staining
for neutrophils and macrophages was conducted. Data
showed significantly increased levels of neutrophilic infiltration
in the non-tumor-bearing SKG and SKG + zymosan lungs as
Figure 2
Kinetics of tumor growth in arthritic versus non-arthritic micer t  i  arthritic versus non-arthritic mice. (a) Mice injected with 4T1 cells; (b) mice injected with TUBO cells. Compared with the 
non-arthritic Balb/c mice, a significant increase in tumor burden was observed in SKG mice challenged with 4T1 (** P < 0.01) and TUBO (* P < 
0.05) cells. Note: All tumor cells were injected in the mammary fat pad and sacrificed four-weeks post tumor challenge. n = 10 mice per group.Page 6 of 15
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Figure 3
Autoimmune arthritis-related inflammation in the lungs is associated with a three-fold increase in the number of lung metastatic lesions in the SKG mice
mice. Representative images of lungs from (a) Balb/c; (b) SKG; (c) SKG + Zymosan A; (d) Balb/c injected with TUBO cells; (e) SKG without 
Zymosan A + TUBO cells; (f) SKG + Zymosan A + TUBO cells (2/8 mice developed lung lesions); (g) Balb/c + 4T1 cells (3/11 mice developed 
lung lesions); (h) SKG without Zymosan A + 4T1 cells (8/8 mice developed severe lung metastasis); (i) SKG + Zymosan A + 4T1 cells (9/9 mice 
developed severe lung metastasis). (j) Percentage of mice that developed lung metastasis. (k and l) H&E of bone section showing high inflammation 
and image of lung with metastasis from the same 4T1-bearing SKG mouse. (m) A statistical analysis for correlation of bone inflammation and lung 
metastasis. The correlation coefficient for the 4T1 tumor-bearing SKG and SKG + Zymosan mice was determined to be 0.93 and 0.90. Correlation 
for TUBO-bearing mice was not calculated. (n to w) H&E staining of the lung sections from (n) SKG (moderate infiltration); (o) SKG + Zymosan A 
(moderate infiltration). (p) Balb/c + TUBO (no inflammation); (q) SKG + TUBO (moderate infiltration); (r) Balb/c + Zymosan A + TUBO; (s) SKG 
+Zymosan A + TUBO (moderate infiltration)(t) Balb/c + 4T1 (no infiltration); (u) SKG + 4T1 (severe infiltration); (v) Balb/c + Zymosan A + 4T1 (no 
infiltration); and (w) SKG + Zymosan A + 4T1 (severe infiltration). The solid filled arrow represents lung metastatic lesions, unfilled arrow represents 
neutrophils and unfilled circles represent macrophages. All images taken at 200 × magnification.
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ures 4a, b, e, and 4h) suggesting a possible role for the infil-
trating neutrophils in attracting the 4T1-tumor cells to the
lungs of the arthritic mice. Not surprising, the neutrophilic infil-
tration was severely elevated with the 4T1 cells but not as
much with the TUBO cells (compare Figures 4g and 4j with 4f
and 4i) implying that the 4T1 metastasis further creates a
stronger chemotactic microenvironment in the lungs of the
arthritic mice to promote additional neutrophilic infiltration. In
the Balb/c mice, neither zymosan injection nor tumor chal-
lenge caused any neutrophilic infiltration in the lungs (Figures
4c and 4d). Although neutrophilic infiltration was most promi-
nent, we detected a few infiltrating macrophages in the SKG
+ zymosan group even without any tumor (Figure 4r), which
was also considerably increased with 4T1 metastasis (Figures
4q and 4t).
BAL fluid from arthritic mice is highly chemotactic for the 
4T1 cells in vitro
Although the data above does not prove, it certainly suggests
that the increased cellular infiltration in the lungs of the arthritic
mice versus the non-arthritic mice may be one of the underly-
ing mechanisms for the increased rate of metastasis observed
in the arthritic mice (Figure 3j). To substantiate the chemotac-
tic potential of the arthritic lung, BAL from lungs of the arthritic
and non-arthritic mice was used as the chemotactic factor in
an in vitro trans-well invasion assay with the 4T1 cells in the
top chamber and BAL in the bottom chamber. Data clearly
shows that BAL collected from the SKG + zymozan or SKG
lungs significantly augment the invasiveness of the 4T1 cells
as compared with the BAL from Balb/c or Balb/c + zymosan
lungs (Figure 4u). Preliminary analysis of the BAL from SKG +
zymozan, and SKG mice showed higher levels of pro-matrix
metalloproteinase (MMP)-9, macrophage colony stimulating
factor (M-CSF) and IL-17 compared with the BAL from Balb/
c + zymozan mice (data not shown).
Increased expression of pancytokeratin positive 
epithelial cells in the arthritic bones coupled with 
increased expression of COX-2
We speculate that the cellular infiltration in the lungs may have
greatly facilitated the recruitment of breast cancer cells to the
site (Figures 3 and 4), so we examined if high cellular infiltra-
tion in the bones of the arthritic mice had a similar effect. We
have already established increased cellular infiltration in the
bones of arthritic versus non-arthritic mice (Figures 1h to 1n),
which was also characterized by neutrophilic infiltration (data
not shown) and osteoclast formation (Figures 1o to 1t). We
now examined the levels of pro-inflammatory factor, COX-2 in
the bone that may create a milieu conducive for increased
bone metastasis. Inflammation in the joints is usually repre-
sented by high levels of COX-2, which also play a critical role
in fostering tumor growth and metastasis [15-18]. In compari-
son to the non-arthritic Balb/c mice with tumor challenge, the
expression of COX-2 in the bones of the arthritic mice was sig-
nificantly greater even without any tumor (Figures 5a, c, e, and
5f), which was undeniably augmented when these arthritic
mice were challenged with the 4T1 tumors (Figures 5b and
5d) but not with TUBO (data not shown). To directly test the
presence of epithelial (tumor) cells in the inflamed bones, sec-
tions of the bone were stained with pancytokeratin antibody.
Increased expression of pancytokeratin-positive areas was
only evident in the bones of the 4T1 tumor-bearing arthritic
mice (Figures 5h and 5j). Bones from all other experimental
groups were negative (Figures 5g, i, k, and 5l). Brown staining
represents COX-2 and pancytokeratin positivity. Bones from
eight mice were examined with similar staining patterns. Thus,
we hypothesize that the pro-inflammatory microenvironment in
the arthritic bone (Figures 1 and 5) may boost the recruitment
of the 4T1 cells and that the 4T1 cells in turn augments the
severity of arthritis (Figure 1); thus creating a highly conducive
microenvironment for the 4T1 tumors to further proliferate.
Increased 4T1 bone lesions in the arthritic versus non-
arthritic mice
Bones from six to seven mice were analyzed by x-ray imaging
for osteolytic lesions. Representative images are shown in Fig-
ures 5m to 5s. Osteolytic and/or sclerotic bone lesions were
determined in 50% (3/6) of SKG mice and 43% (3/7) of the
SKG + zymosan mice challenged with the 4T1 metastatic
tumor cells (Figures 5r, s, and 5t). These bones show distinct
radiolucencies in the distal femoral diametaphysis, proximal
tibia and head of humerus indicating apparent osteolytic bone
lesion (as indicated by the arrows; Figures 5r and 5s). In con-
trast, none of the Balb/c mice challenged with 4T1 or TUBO
tumors developed bone lesions (Figures 5m to 5o) nor did any
of the SKG mice challenged with TUBO cells (Figures 5p and
5q). The results confirm that bone lesions only occur in the
pro-arthritic and arthritic bones but not in non-arthritic bones
(Figure 4t). Taken together, data from Figures 1 and 5 imply
that cellular infiltration and osteoclast formation along with
increased COX-2 may provide a conducive microenvironment
for 4T1 tumor cells to metastasize to the bone, which further
augments cellular infiltration and osteoclast formation associ-
ated with increased bone damage completing the vicious
cycle of osteolytic bone metastasis [19].
M-CSF, IL-6, IL-17, TNF-α, and VegF may be the 
underlying factors responsible for the increased 
metastasis in the arthritic mice
To determine the possible mechanism that drives the 4T1 cells
to become more metastatic in the arthritic model, we evaluated
the circulating levels of pro-inflammatory cytokines and chem-
okines in the sera of the arthritic versus the non-arthritic mice.
A custom mouse cytokine array was designed to test the sera
for the presence of 10 cytokines known to be associated with
osteolysis as well as tumor growth and metastasis [19]. These
included M-CSF, TNF-α, interferon-gamma (IFN-γ), vascular
endothelial growth factor (VegF), IL-17, MMP-2, IL-6, Insulin-
like growth factor-II (IGF-II), IL-1β, and IL-4 (Figure 6a). Com-Page 8 of 15
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Figure 4
Increased infiltration of neutrophils and macrophages in the arthritic SKG mice versus the non-arthritic Balb/c mice. (a to j) Naphthol AS-D chloroa-
cetate esterase staining of the lungs staining for neutrophils. (a) Balb/c; (b) Balb/c + Zymosan; (c) Balb/c + Zymosan + TUBO; (d) Balb/c + 
Zymosan + 4T1; (e) SKG (moderate infiltration of neutrophils); (f) SKG + TUBO(moderate infiltration); (g) SKG + 4T1(severe infiltration of neu-
trophils); (h) SKG + Zymosan(moderate infiltration); (i) SKG + Zymosan + TUBO (moderate infiltration); (j) SKG + Zymosan +4 T1(severe infiltra-
tion of neutrophils). No infiltration of neutrophils observed in any other experimental groups. (k to t) F4/80 staining of the lungs showing 
macrophages. (k) Balb/c; (l) Balb/c + Zymosan; (m) Balb/c + Zymosan + TUBO; (n) Balb/c + Zymosan + 4T1; (o) SKG; (p) SKG + TUBO; (q) 
SKG +4T1 (increased macrophages); (r) SKG + Zymosan (few macrophages); (s) SKG + Zymosan + TUBO (few macrophages); (t) SKG + 
Zymosan + 4T1 (increased infiltration of macrophages). No infiltrating macrophages observed in any other experimental groups. (u) BAL fluid from 
arthritic lungs caused significant increase in invasiveness of the 4T1 cells as compared with the BAL from non-arthritic lungs. All images taken at 
200 × magnification. All slides were examined by the histology personnel and Dr Gruber at the Carolinas Medical Center confirming neutrophil 
infiltration.
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Figure 5
Increased expression of COX-2 and pancytokeratin in the bones of arthritic mice challenged with 4T1 cells-   a yt k r ti  in the bones of arthritic mice challenged with 4T1 cells. Bone sections from various experimental 
groups (indicated in the Figure) stained for COX-2 (a to f) and pancytokeratin (g to l). Brown staining represents positive staining. All images taken 
at 200 × magnification. (m to s) Representative Faxitron x-ray images of bones. (m) Balb/c + TUBO; (n) Balb/c + 4T1; (o) Balb/c + Zymosan + 
4T1; (p) SKG + TUBO; (q) SKG + Zymosan + Tubo; (r) SKG + 4T1 (showing small radiolucencies in distal femur, proximal tibia, and head of 
humerus indicating apparent osteolytic bone lesions); (s) SKG + Zymosan A + 4T1 (showing radiolucencies in the distal femur, proximal tibia and 
head of humerus possibly due to osteolytic bone lesion). Six to seven mice from each group were examined using the faxitron x-ray. No lytic or scle-
rotic lesions were observed in any other experimental group. (t) Percentage of mice that developed bone metastasis.
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Figure 6
Serum analysis of cytokines revealed up regulation of several cytokines in the arthritic mice compared with the non-arthritic mice, and treatment with IL-17 antibody and celecoxib completely prevented formation of lung metastasis in the SKG mice
IL-17 antibody and celecoxib completely prevented formation of lung metastasis in the SKG mice. (a) Array template of the cytokines on the mem-
brane. Up-regulation of macrophage colony stimulating factor (M-CSF), TNF-alpha, IL-17, vascular endothelial growth factor (VegF), and IL-6 is 
observed and highlighted in gray on the template (b to g) Membrane dot blot representing circulating cytokine levels in various groups of mice (indi-
cated in the Figure). Boxes are drawn around the cytokines that were up-regulated. (h) A graphical representation of the up-regulated cytokines 
observed on the membrane blots based on densitometry analysis (n = 4 mice). (i) Significant reduction in tumor burden in mice treated with 
celecoxib (P < 0.05), α-IL-17 antibody (P < 0.01) or α-IL-17 antibody + celecoxib (P < 0.01) as compared with the untreated or IgG isotype group; 
(j) Percentage of mice that developed lung metastasis. (k) Schematic model depicting the vicious interaction between metastatic breast tumors and 
the inflammatory microenvironment in the bone and lung due to autoimmune arthritis (AA). During arthritis, inflammatory cell infiltrate in the bones and 
lungs trigger the release of pro-inflammatory cytokines. These cytokines act directly or indirectly on the primary breast tumor cells enhancing their 
metastatic ability. The ensuing damage to the bones and the large amounts of inflammatory cells in the bones and lungs of the arthritic mice allows 
retention and growth of the tumor cells in the site. The final distribution of metastasis reflects the relative abundance of inflammation in the organs. 
Thus, we hypothesize that the increase in some of the proinflammatory cytokines such as IL-17 may be the underlying factor responsible for the 
increased metastasis.
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increase in the levels of M-CSF (1.5 fold), IL-17 (1.5 fold),
TNF-α, VegF, and IL-6 (1.2 fold) was observed in the 4T1
tumor-bearing arthritic mice (Figures 6e to 6g). A graphical
representation of the values from the densitometric analysis is
provided in Figure 6h. In the TUBO-bearing mice, the increase
was non-significant between Balb/c and the arthritic mice (Fig-
ures 6b to 6c). Serum from SKG + zymosan mice (without
tumor challenge) was used as control and the cytokine levels
was found to be similar to that found in sera of SKG +
zymosan + TUBO and SKG + TUBO mice (Figure 6h) imply-
ing that the increase in the cytokine levels was not just a func-
tion of zymosan injection but was driven by a combination of
arthritic milieu and metastatic 4T1 tumors but not by either
condition alone.
Treatment with anti-IL17 treatment in combination with 
celecoxib prevents 4T1-associated metastasis in the 
SKG mice
IL-17 was elevated in our model, and because it is an emerg-
ing therapeutic target for cancer metastasis and arthritis [20-
26], we tested if neutralizing IL-17 will be an effective therapy
against the development of secondary metastasis in our
arthritic model. We elected to conduct treatment with an anti-
IL-17 antibody either alone or in combination with celecoxib, a
selective COX-2 inhibitor, in the SKG mice with established
4T1 tumors. The rationale for using a specific COX-2 inhibitor
was that these drugs including celecoxib were originally devel-
oped for treating arthritis but have now been shown to have
significant anti-cancer properties [27,28]. Established 4T1
tumor burden was significantly reduced in mice treated with
celecoxib (P < 0.05), α-IL-17 antibody (P < 0.01), or celecoxib
+ α-IL-17 antibody (P < 0.01) when compared with untreated
or control antibody + vehicle (DMSO) treated mice (Figure 6i).
More importantly, mice treated with the combination of
celecoxib + α-IL-17 antibody were completely spared of lung
metastasis (Figure 6j.) and only 10% of the mice (1/10 mice)
in the α-IL-17 antibody group developed lung metastasis com-
pared with 80% (8/10 mice) in the celecoxib-treated and
100% (10/10 mice) in the untreated or control antibody +
vehicle-treated mice (Figure 6j).
Discussion
A significant increase in breast cancer-associated secondary
metastasis to the lungs and bones were observed in the
arthritic versus the non-arthritic mice (Figures 3 and 5) along
with increase in primary tumor burden (Figure 2). In addition,
the metastatic breast cancer 4T1 cells accentuate the severity
of bone destruction and lung inflammation in the arthritic mice
creating a favorable microenvironment for the tumor cells to
grow (Figures 1, 3, and 4). We therefore suggest that chronic
inflammation in the bone and lung caused by AA and the sub-
sequent increase in circulating levels of proinflammatory
cytokines may be the underlying mechanism for the increased
metastasis (Figure 6). This is further substantiated when treat-
ment with celecoxib + αIL-17 antibody completely protected
the arthritic mice from 4T1 metastasis (Figure 6j), as well as
significantly reduced established primary tumor (Figure 6i).
Compared with the non-arthritic Balb/c mice, the lungs of the
arthritic mice expresses high levels of cellular infiltrates mostly
characterized by neutrophils and some macrophages even
before any tumor challenge (Figures 4h and 4r) suggesting a
pro-inflammatory milieu that may be responsible for attracting
the 4T1 metastatic cells to the lungs as demonstrated in the in
vitro invasion assay (Figure 4u). Similar low-level inflammation
(as characterized by COX-2 staining and cellular infiltration) is
also observed in the bones of the arthritic mice prior to tumor
challenge, which is completely absent in the non-arthritic Balb/
c bones (Figures 1 and 5). Once the 4T1 cells home to the
lungs or bones, the level of interstitial inflammatory cellular infil-
trates is exponentially increased characterized by prominent
neutrophils and macrophages (Figures 1, 3, and 4). These pro-
inflammatory leukocytes alone can facilitate tumor cell extrava-
sation and promote metastasis [29]. Thus, it is not surprising
that we saw an increase in pro-inflammatory and pro-ang-
iogenic cytokines in the serum of these 4T1 tumor-bearing
arthritic mice versus the Balb/c non-arthritic mice (Figure 6h).
This is the first study that undoubtedly establishes a correla-
tion between the pro-inflammatory cell recruitment in the lungs
during AA and the homing of the circulating tumor cells in the
inflamed lungs (Figures 3 and 4). In the bone, once the meta-
static breast cancer cells get attracted to the inflamed bone
milieu (Figures 1 and 5), they produce unknown factors that
directly or indirectly induce osteoclast formation (Figure 1)
causing bone resorption and release of growth factors from
the bone matrix which in turn stimulates further tumor growth
(schematically illustrated in Figure 6k) and reviewed in [19].
This reciprocal interaction between breast-cancer cells and
the bone microenvironment results in a vicious cycle that
increases both bone destruction and increases tumor burden
and metastasis (Figure 6k) [19].
As in human AA, cytokines play an essential role in the devel-
opment of arthritis in the SKG mice [9,30]. Several cytokines
have been implicated in the mechanism of synovial cell activa-
tion and joint destruction in AA [31]. In our study, serum anal-
ysis of cytokine proteins revealed higher expression of M-CSF,
IL-17, IL-6, TNF-α, and VegF in the arthritic mice only when
challenged with 4T1 metastatic breast cancer cells (Figure
6h). Elevated serum M-CSF predicts reduced survival in met-
astatic breast cancer patients [32,33]. The M-CSF produced
by breast cancer cells and surrounding stroma increases oste-
oclast formation and maturation and enhances the expression
of stromal RANK ligand, both of which increase osteolytic
bone degradation [34]. IL-17 has been identified as a crucial
cytokine for osteoclastic bone resorption in AA patients [24].
IL-17 acts on osteoblasts by stimulating COX-2-dependent
prostaglandin E2 (PGE2), and osteoclast differentiation factor,Page 12 of 15
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Available online http://breast-cancer-research.com/content/11/4/R56which differentiates osteoclast progenitors into mature osteo-
clasts, causing bone resorption. PGE2 interacts with its
eicosanoid receptors to induce the damage [24]. IL-17 is also
known to be upregulated in breast and other cancers [35-37].
IL-6 is an autocrine and paracrine growth factor for several
cancers, including breast cancer [38,39] and stimulates can-
cer cell growth and contributes to recurrence and metastasis
in breast cancer [40]. TNF-α is a known pro-inflammatory
cytokine and generates an autocrine tumor promoting network
in ovarian and breast cancer [41]. VegF is known to play a crit-
ical role in vasculogenesis, angiogenesis, and metastasis [42-
44]. Upregulation of these cytokines may therefore account for
the enhanced breast cancer-associated secondary metastasis
as well as accentuating the severity of arthritis in the SKG
mice. Thus, blocking these pro-inflammatory cytokines may
hold promise in reducing the severity of both diseases. Indeed
when we blocked the IL-17 pathway, we observed a signifi-
cant reduction in established primary tumor burden and even
more significant reduction in rate of metastasis (Figures 6i and
6j). The effect was even greater when IL-17 blockade was
combined with blocking the COX-2 pathway where none of
the mice treated with the combination developed any metasta-
sis (Figure 6j).
Inflammation is a critical hallmark of arthritis and tumor pro-
gression [2,45-47]. Many processes that occur during arthritis
also occur during tumorigenesis. There is increased vascular-
ity in both, and there are common cytokines and growth fac-
tors that are regulated in both. The microenvironment in the
tumor and arthritis is largely orchestrated by inflammatory cells
and growth factors [48,49]. Thus, it is not unlikely that the two
diseases commonly co-exist in women. Our study begins to
evaluate whether these two disease states molecularly interact
and feed off each other. Data from these studies were further
substantiated in our preliminary study using a spontaneous
metastatic breast cancer model (mice expressing the polyoma
middle T antigen driven by the MMTV promoter) [50] that
develop collagen-induced arthritis [51]. Similar increases in
bone and lung metastasis is noted in this model as well
(unpublished data). These studies may have important clinical
implications, especially in the prevention of secondary
metastasis, in designing combination drug regimens, and as a
diagnostic risk-assessment tool.
Conclusions
Our data provide clear evidence for the first time that breast
cancer-associated secondary metastasis is significantly
increased in pro-arthritic and arthritic conditions and that
blocking the IL-17 and COX-2 pathway may significantly
reduce the rate of metastasis.
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